Novartis Plans Debt Raise for Avidity Biosciences Acquisition

Novartis AG is planning to raise debt to support its $12 billion acquisition of Avidity Biosciences Inc. Bloomberg posted on X, highlighting this move as part of a series of mergers and acquisitions financing deals. The acquisition aims to enhance Novartis's portfolio and strengthen its position in the biosciences sector. This strategic financial decision reflects the company's commitment to expanding its capabilities and market presence.